Enterprise Therapeutics initiates a Phase I study of its novel TMEM16A potentiator, ETD002, for the treatment of cystic fibrosis

Enterprise Therapeutics, a drug discovery company that develops novel therapies for the treatment of respiratory diseases, announced it has successfully started the first-in-man safety Phase 1 study of its novel inhaled cystic fibrosis therapy, ETD002.

Previously, in pre-clinical models, the company has demonstrated that ETD002 enhances the activity of TMEM16A (ANO1, anoctamin-1), a calcium-activated chloride channel expressed in airway secretory epithelia, increases epithelial fluid secretion and enhances mucus clearance. Importantly, these effects of ETD002 are independent of CFTR function. Therefore, TMEM16A potentiation is regarded as a promising novel approach for the treatment of patients with CF and also non-CF lung diseases.

Read the press release here.

Read more about Enterprise Therapeutics here.

Photo by Robina Weermeijer on Unsplash